Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06275685

Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking

The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy.

The main questions it aims to answer are:

* can we develop a future seizure probabilities tool that is more accurate than chance based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables. * does this tool improve the lives of people with epilepsy?

Researchers will compare a group that does not have access to the forecast tool to a group that does and see if it is accurate and if people with it report that it improved their quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Epilepsy; Seizure Brain Diseases Central Nervous System Diseases Epilepsy Nervous System Diseases

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The primary goal of the study is to demonstrate the accuracy of SeizureWise in predicting the timing of future convulsive seizures using data collected by the wearable EmbracePlus device and data provided by patients with GTCS monitored in outpatient settings.

The secondary goals are:

to assess the clinical impact of SeizureWise on quality of life (QoL), psychological health indicators, and economic and clinical outcomes to assess the clinical impact of visualizing behavioral and physiologic data without forecasting predictions on quality of life (QoL), psychological health indicators, and economic and clinical outcomes

A non-significant risk, open-label, prospective, randomized clinical investigation designed to evaluate the ability of SeizureWise to forecast GTCS occurrence and to assess impact on QoL and seizure management outcomes.

The study will include two phases during which an algorithm based on sensor derived physiological measures is developed and tested with output blinded to the participant. In a final phase participants will be randomized to two arms, one of which will have access to a seizure forecasting risk score.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be diagnosed with or be at risk of epilepsy
  • Subjects or their parents or guardians must understand and consent to be in the study;
  • Subjects or their parents or guardians must be able to read and communicate in English;
  • Subjects or their parents or guardians must be willing and able to comply with study procedures and duration;
  • Subjects must have a wrist circumference suitable for wearing the EmbracePlus device.

Exclusion criteria

  • Subjects, or their parents or guardians for minor study participants, who do not understand the study and the risks;
  • Subjects, or their parents or guardians for minor study participants, who are either physically or cognitively incapable of performing study activities (e.g. filling in surveys and daily e-diary);
  • Subjects who would be placed at undue medical risk associated with any procedure called for in the protocol; or
  • Subjects that are Empatica employees and actively participated in the development of this protocol or development of the Seizure Wise algorithms.

Treatment and study plan

SeizureWise algorithm

Device

An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables

Multi-day Visualizations

Device

Multi-day visualizations of sensor derived data

Primary outcomes

  1. Sensitivity of SeizureWise

    Time frame: 2 years

    Percentage of patients with (1) sensitivity of high-likelihood warnings greater than 60% and (2) superior to a rate-matched forecast (or superior baselining method) at the end of Phase 2.

Secondary outcomes

  1. Change in QoL and psychological health indicators using the Quality of life in epilepsy (QOLIE-10-P)

    Time frame: 2 years

    Changes in QoL and psychological health indicators pre- and post-Phase 3 (cross-arm and intra-arm comparisons. This will be assessed using the QOLIE-10-P and scored according to these guidelines https://www.aan.com/siteassets/home-page/policy-and-guidelines/quality/quality-measures/epilepsy-and-seizures/qolie10p-scoring.pdf

  2. Qualitative assessment of multi-day visualizations

    Time frame: 2 years

    Patient-reported qualitative assessment of multi-day visualizations to the patient during Phase 3 (both arms). This will be assessed using a custom survey and a qualitative analysis of the scores will be performed between start of phase 3 (with no visualizations) and during and at the end of phase 3 when visualizations have been provided to the user.

  3. Stress level with visualizations using the brief epilepsy anxiety survey instrument (brEASI-8)

    Time frame: 2 years

    Quantitative patient report of stress level pre- and post- forecast visualization during Phase 3 in the intervention arm. This will be assessed using brEASI-8 where a lower score indicates a lower stress level.

  4. Modifiable behavior change

    Time frame: 2 years

    Adjustment in modifiable behaviors during Phase 3 based on multi-day visualizations (boths arms) and forecast outputs (intervention arm). This will be assessed using a custom survey and a qualitative analysis will be performed that looks at participants behaviors before and after receiving visualizations and SeizureWise.

  5. Accuracy of SeizureWise low-likelihood forecast

    Time frame: 2 years

    Percentage of time in a low-likelihood forecast category during which no seizure event occurs during Phase 2.

  6. Accuracy of SeizureWise high-likelihood forecast

    Time frame: 2 years

    Percentage of time in a high-likelihood forecast category during which a seizure event occurs during Phase 2.

Study contacts

Contact information is provided by the study sponsor or research team.

Empatica Support

CONTACT

[email protected]

855-830-3531

Sponsors and collaborators

Lead sponsor

Empatica, Inc.

Industry

Registry information

Acronym: Foresight

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 23, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.